Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $279,208.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,700 shares of Guardant Health stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total value of $279,208.00. Following the completion of the transaction, the director owned 4,556 shares of the company’s stock, valued at approximately $748,277.44. The trade was a 27.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The stock was sold at an average price of $130.06, for a total value of $130,060.00.
• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.

Guardant Health Price Performance

NASDAQ:GH opened at $168.48 on Friday. Guardant Health, Inc. has a 12-month low of $51.44 and a 12-month high of $176.58. The firm has a market capitalization of $22.61 billion, a P/E ratio of -48.27 and a beta of 1.60. The business has a 50 day simple moving average of $147.02 and a 200 day simple moving average of $115.20.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GH shares. Sanford C. Bernstein upped their price target on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. Morgan Stanley boosted their target price on shares of Guardant Health from $175.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Stifel Nicolaus raised their price target on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Stephens lifted their price target on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Bank of America boosted their price objective on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Hedge Funds Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health during the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at approximately $35,000. Parallel Advisors LLC raised its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Finally, Ascentis Independent Advisors bought a new stake in Guardant Health during the first quarter worth approximately $38,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.